A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

NCT01469000 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non Small Cell Lung

Interventions

DRUG: Gefitinib
DRUG: Pemetrexed

Sponsor

Eli Lilly and Company